Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape [Seeking Alpha]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Seeking Alpha
1 Like BioCGT Investor Follower s Follow Summary Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations. Despite competition from Eli Lilly and Novo Nordisk, VK2735's unique oral formulation could position Viking as a strong contender in the obesity drug market. VKTX's financial stability, with $942 million in cash and equivalents, supports its ongoing and future clinical trials, making it a viable long-term investment. I rate Viking Therapeutics as a "Buy" for high-risk tolerant investors, driven by VK2735's potential and additional upside from VK2809 and preclinical assets. Tim Platt/DigitalVision via Getty Images Thesis Viking Therapeutics ( NASDAQ: VKTX ) is a biotechnology company in the clinical stage focused on the discovery and development of novel treatments for metabolic and endocrinology disorders. Viking's most promisin
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now. [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735 [Yahoo! Finance]Yahoo! Finance
- Why Investors Plowed Into Viking Therapeutics Stock Today [Yahoo! Finance]Yahoo! Finance
- Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (NASDAQ: VKTX) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $105.00 price target on the stock.MarketBeat
VKTX
Earnings
- 7/24/24 - Beat
VKTX
Sec Filings
- 8/22/24 - Form 4
- 8/22/24 - Form 4
- 8/21/24 - Form 144
- VKTX's page on the SEC website